Effects of Ranolazine on Wild-Type and Mutant hNav1.7 Channels and on DRG Neuron Excitability
Open Access
- 1 January 2010
- journal article
- Published by SAGE Publications in Molecular Pain
- Vol. 6 (1), 35
- https://doi.org/10.1186/1744-8069-6-35
Abstract
Background: A direct role of sodium channels in pain has recently been confirmed by establishing a monogenic link between SCN9A, the gene which encodes sodium channel Nav1.7, and pain disorders in humans, with gain-of-function mutations causing severe pain syndromes, and loss-of-function mutations causing congenital indifference to pain. Expression of sodium channel Nav1.8 in DRG neurons has also been shown to be essential for the manifestation of mutant Nav1.7-induced neuronal hyperexcitability. These findings have confirmed key roles of Nav1.7 and Nav1.8 in pain and identify these channels as novel targets for pain therapeutic development. Ranolazine preferentially blocks cardiac late sodium currents at concentrations that do not significantly reduce peak sodium current. Ranolazine also blocks wild-type Nav1.7 and Nav1.8 channels in a use-dependent manner. However, ranolazine's effects on gain-of-function mutations of Nav1.7 and on DRG neuron excitability have not been investigated. We used voltage- and current-clamp recordings to evaluate the hypothesis that ranolazine may be effective in regulating Nav1.7-induced DRG neuron hyperexcitability. Results: We show that ranolazine produces comparable block of peak and ramp currents of wild-type Nav1.7 and mutant Nav1.7 channels linked to Inherited Erythromelalgia and Paroxysmal Extreme Pain Disorder. We also show that ranolazine, at a clinically-relevant concentration, blocks high-frequency firing of DRG neurons expressing wild-type but not mutant channels. Conclusions: Our data suggest that ranalozine can attenuate hyperexcitability of DRG neurons over-expressing wild-type Nav1.7 channels, as occurs in acquired neuropathic and inflammatory pain, and thus merits further study as an alternative to existing non-selective sodium channel blockers.Keywords
This publication has 35 references indexed in Scilit:
- Block of Tetrodotoxin-sensitive, Nav1.7, and Tetrodotoxin-resistant, Nav1.8, Na+channels by RanolazineChannels, 2008
- State- and Use-Dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-Gated Na+ Channel Isoforms by RanolazinePublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2007
- Pharmacologic management of neuropathic pain: Evidence-based recommendationsPain, 2007
- From genes to pain: Nav1.7 and human pain disordersTrends in Neurosciences, 2007
- Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial FibrillationCirculation, 2007
- Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotypeNature Neuroscience, 2007
- Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazineHeart, 2006
- Molecular basis of ranolazine block of LQT‐3 mutant sodium channels: evidence for site of actionBritish Journal of Pharmacology, 2006
- Ranolazine Improves Abnormal Repolarization and Contraction in Left Ventricular Myocytes of Dogs with Heart Failure by Inhibiting Late Sodium CurrentJournal of Cardiovascular Electrophysiology, 2006
- Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic PropertiesCirculation, 2004